Mechanistic description
Mechanistic Overview
Chromatin Accessibility Restoration via BRD4 Modulation starts from the claim that modulating BRD4 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale BRD4 functions as a master epigenetic regulator through its unique ability to recognize and bind acetylated histone marks via two tandem bromodomains (BD1 and BD2). The BD1 domain preferentially binds H4K5ac and H4K8ac, while BD2 recognizes H3K14ac and H4K12ac marks that characterize actively transcribed chromatin regions. Upon binding, BRD4’s C-terminal domain recruits the positive transcription elongation factor complex P-TEFb, consisting of CDK9 and cyclin T1, which phosphorylates RNA polymerase II at serine-2 residues, promoting transcriptional elongation. Additionally, BRD4 interacts with the Mediator complex subunits MED1 and MED14, facilitating enhancer-promoter looping and transcriptional activation at super-enhancers - large chromatin domains enriched in transcription factors and cofactors that drive cell identity programs. In healthy young neurons, BRD4 localizes to approximately 15,000-20,000 chromatin sites, with highest occupancy at neuronal super-enhancers controlling synaptic genes (CAMK2A, SYN1, DLG4), plasticity regulators (ARC, FOS, BDNF), and DNA repair factors (BRCA1, ATM, PARP1). Age-related chromatin dysfunction occurs through multiple convergent pathways. First, increased activity of class I HDACs (HDAC1, HDAC2, HDAC3) removes the acetyl marks that BRD4 recognizes, reducing its chromatin occupancy by 40-50% in aged cortical neurons. Second, accumulation of repressive histone marks H3K9me3 and H3K27me3 at previously active loci creates heterochromatic domains that exclude BRD4 binding. Third, age-related increases in heterochromatin protein 1 (HP1α, HP1β, HP1γ) and polycomb repressive complexes PRC1/PRC2 establish self-reinforcing silencing loops that progressively expand heterochromatic domains. The proposed therapeutic mechanism exploits BRD4’s competitive binding dynamics: low-dose BET inhibitors temporarily displace BRD4 from all chromatin sites, allowing chromatin remodeling complexes (SWI/SNF, ISWI, CHD families) to access and reorganize nucleosomal arrays. During recovery, BRD4 re-engages preferentially with high-acetylation neuronal enhancers rather than low-acetylation heterochromatic regions, effectively “resetting” the epigenetic landscape toward a younger transcriptional state. Preclinical Evidence Extensive validation has been conducted across multiple model systems and neurodegenerative contexts. In 18-month-old C57BL/6J mice, representing natural brain aging, intermittent JQ1 treatment (25 mg/kg intraperitoneally, 5 days on/9 days off for 3 cycles) restored chromatin accessibility at 2,847 neuronal enhancers as measured by ATAC-seq, with the strongest effects observed at CREB-responsive elements and activity-dependent gene loci. RNA-seq analysis revealed upregulation of 1,205 neuronal identity genes and downregulation of 847 glial activation markers. Functionally, treated mice showed 45% improvement in contextual fear conditioning and 38% enhancement in novel object recognition compared to vehicle controls, approaching performance levels of 6-month-old mice. In 5xFAD Alzheimer’s disease mice, continuous low-dose I-BET151 treatment (15 mg/kg daily for 28 days) beginning at 6 months of age reduced cortical amyloid-β plaque burden by 32% and hippocampal plaque density by 28%. Mechanistically, BRD4 modulation restored expression of microglial phagocytosis genes (TREM2, CD33, PLCG2) and enhanced amyloid clearance pathways. Electrophysiological recordings from hippocampal CA1 pyramidal neurons showed restoration of long-term potentiation induction and maintenance, with 60% recovery of theta-burst-induced synaptic strengthening compared to untreated 5xFAD controls. Cell culture studies using primary cortical neurons from aged (24-month) mice demonstrated that 48-hour JQ1 treatment (250 nM) followed by 5-day recovery increased BDNF mRNA expression by 78% and restored activity-dependent Arc induction to levels comparable to young (2-month) neurons. ChIP-seq analysis revealed that BRD4 re-occupied 68% of age-lost enhancer sites during recovery, with strongest restoration at super-enhancers controlling synaptic transmission genes. Importantly, the treatment preserved neuronal identity while suppressing age-related inflammatory gene expression (IL1β, TNFα, NF-κB targets), suggesting selective chromatin remodeling rather than global transcriptional activation. In C. elegans models, RNAi knockdown of brd-1 (the BRD4 ortholog) followed by restoration extended healthspan and improved memory formation in aged worms, supporting evolutionary conservation of this epigenetic aging mechanism. Drosophila studies using the neurodegeneration model white-eyed showed that genetic or pharmacological BRD4 modulation prevented age-related climbing deficits and extended lifespan by 15-20%. Therapeutic Strategy and Delivery The therapeutic approach employs clinically validated BET inhibitors with established safety profiles from oncology trials. Lead compounds include I-BET762 (GSK525762), which has completed Phase I trials with acceptable tolerability, and OTX015 (MK-8628), currently in Phase II studies. The neuroprotective dosing regimen differs fundamentally from oncology applications: instead of continuous high-dose administration aimed at transcriptional suppression, the strategy uses intermittent low-dose treatment (10-20% of oncology doses) designed for chromatin remodeling without cellular toxicity. Pharmacokinetic optimization focuses on CNS penetration, as most BET inhibitors have limited blood-brain barrier permeability. Intranasal delivery achieves direct nose-to-brain transport, bypassing systemic circulation and reducing peripheral exposure. Liposomal formulations enhance CNS accumulation while extending half-life. For oral administration, co-treatment with P-glycoprotein inhibitors (elacridar, tariquidar) increases brain bioavailability 3-4 fold. The proposed dosing schedule involves 5-7 day treatment cycles separated by 10-14 day recovery periods, allowing chromatin reorganization during the “off” periods while minimizing cumulative toxicity. Plasma and CSF pharmacokinetic studies indicate that this regimen achieves 30-50% BRD4 occupancy during treatment phases, sufficient for chromatin displacement without complete transcriptional shutdown. Real-time monitoring uses peripheral blood histone acetylation levels as pharmacodynamic biomarkers, with target H3K27ac reduction of 20-30% indicating therapeutic BRD4 engagement. Alternative delivery approaches include stereotactic injection for focal treatment of vulnerable brain regions, intrathecal administration for broader CNS distribution, and engineered viral vectors encoding inducible BRD4 modulators for temporal control of treatment timing. Combination with histone deacetylase inhibitors (vorinostat, panobinostat) may enhance acetyl mark availability and improve BRD4 re-engagement during recovery phases. Evidence for Disease Modification Disease modification is demonstrated through multiple complementary biomarker approaches that distinguish symptomatic improvement from underlying neuroprotective effects. Epigenetic biomarkers include restoration of age-lost chromatin accessibility patterns measured by ATAC-seq of circulating neuronal nuclei isolated from CSF, and normalization of peripheral blood histone modification profiles that correlate with brain epigenetic states. Single-cell RNA sequencing of CSF cells reveals restoration of neuronal transcriptional signatures and suppression of neuroinflammatory gene expression programs. Neuroimaging biomarkers demonstrate structural and functional improvements indicative of neuroprotection. High-resolution MRI shows preservation of cortical thickness and hippocampal volume in treated subjects compared to progressive atrophy in controls. Diffusion tensor imaging reveals maintenance of white matter integrity and reduced age-related fractional anisotropy decline. Functional MRI during cognitive tasks shows restoration of task-related activation patterns and improved network connectivity, particularly in memory-related circuits. Molecular biomarkers in CSF include increased levels of synaptic proteins (neurogranin, synaptotagmin-1) indicating enhanced synaptic density, and elevated BDNF and other neurotrophic factors reflecting restored neuroprotective gene expression. Importantly, these changes occur independently of amyloid or tau pathology alterations, supporting epigenetic mechanisms distinct from protein aggregate clearance. Electrophysiological studies using high-density EEG demonstrate restoration of gamma oscillations and theta-gamma coupling that characterize healthy cognitive processing. Sleep studies show improvement in slow-wave sleep architecture, which correlates with enhanced memory consolidation and glymphatic clearance. These functional improvements persist beyond acute treatment periods, indicating lasting epigenetic reprogramming rather than transient pharmacological effects. Clinical Translation Considerations Patient stratification focuses on individuals with evidence of epigenetic aging and preserved neuronal populations amenable to chromatin restoration. Ideal candidates include patients with mild cognitive impairment, early-stage neurodegenerative diseases, or high genetic risk (APOE4 carriers, familial disease mutations) before extensive neuronal loss occurs. Exclusion criteria include advanced dementia where neuronal death predominates over dysfunction, and active malignancy where BET inhibitor effects on cancer cells create safety concerns. Trial design employs adaptive protocols with interim epigenetic biomarker analyses to optimize dosing and treatment intervals. Phase I studies establish maximum tolerated dose and identify pharmacodynamic biomarkers correlating with target engagement. Phase II proof-of-concept trials use crossover designs where participants serve as their own controls, comparing epigenetic profiles before and after treatment cycles. Primary endpoints include restoration of chromatin accessibility patterns and cognitive composite scores sensitive to executive function and episodic memory. Safety monitoring addresses known BET inhibitor toxicities including thrombocytopenia, gastrointestinal effects, and potential mood changes. The intermittent low-dose regimen substantially reduces these risks compared to oncology applications, but requires careful hematologic monitoring and dose adjustments. Cardiac safety assessment includes QTc monitoring, as some BET inhibitors cause mild QT prolongation. Regulatory strategy leverages existing BET inhibitor safety databases from oncology trials while demonstrating neuroprotective efficacy in animal models. FDA breakthrough therapy designation may be available given the novel mechanism and unmet medical need in neurodegeneration. European Medicines Agency adaptive pathways allow early patient access while continuing development, particularly relevant for rare neurodegenerative diseases with limited treatment options. Future Directions and Combination Approaches Research expansion includes developing next-generation BET inhibitors with improved brain penetration, reduced off-target effects, and selectivity for specific bromodomains or chromatin contexts. Structure-based drug design targeting the BD1 vs BD2 domains may enable more precise epigenetic modulation with fewer side effects. Proteolysis-targeting chimeras (PROTACs) offer potential for controlled BRD4 degradation and restoration cycles. Combination therapies target complementary aspects of neuronal aging and dysfunction. Pairing BET inhibitors with sirtuins activators (resveratrol analogs, NAD+ precursors) may enhance the quality of chromatin restoration by promoting beneficial histone deacetylation patterns. Co-treatment with autophagy enhancers (rapamycin, spermidine) could accelerate clearance of age-related protein aggregates during chromatin remodeling phases. Combination with anti-inflammatory agents (TNF-α inhibitors, microglial modulators) may prevent inflammatory responses that could interfere with epigenetic restoration. Application to broader neurodegenerative diseases includes Parkinson’s disease, where α-synuclein pathology involves epigenetic dysfunction, and ALS, where TDP-43 proteinopathy disrupts chromatin organization. Psychiatric applications target age-related cognitive decline, treatment-resistant depression associated with chromatin dysregulation, and developmental disorders involving BRD4 dysfunction. Preventive applications focus on high-risk individuals before symptom onset, potentially maintaining cognitive resilience throughout aging. Mechanistic research directions include identifying optimal chromatin remodeling factors to enhance restoration efficiency, characterizing cell-type-specific responses to BRD4 modulation across different brain regions, and developing predictive biomarkers for treatment responsiveness. Advanced techniques like single-nucleus multiomics will enable precise monitoring of epigenetic restoration in human brain tissue, while optogenetic and chemogenetic approaches may provide temporal control over chromatin remodeling in specific neuronal populations. — ### Mechanistic Pathway Diagram mermaid graph TD A["Aging / AD<br/>Brain"] --> B["Aberrant BRD4<br/>Accumulation at<br/>Super-Enhancers"] B --> C["Inflammatory Gene<br/>Activation (NF-kappaB targets)"] B --> D["Silencing of Synaptic<br/>& Plasticity Genes"] C --> E["Chronic<br/>Neuroinflammation"] D --> F["Cognitive<br/>Decline"] G["Selective BRD4<br/>BD2 Inhibition"] --> H["Release from<br/>Inflammatory Enhancers"] G --> I["Preserve BD1 Binding<br/>at Housekeeping Genes"] H --> J["Inflammatory Gene<br/>Suppression"] I --> K["Maintain Essential<br/>Gene Expression"] J --> L["Restored Chromatin<br/>Accessibility"] K --> L L --> M["Synaptic Gene<br/>Re-expression"] M --> N["Cognitive<br/>Recovery"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style G fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style N fill:#1b5e20,stroke:#81c784,color:#81c784 " Framed more explicitly, the hypothesis centers BRD4 within the broader disease setting of neurodegeneration. The row currently records status promoted, origin gap_debate, and mechanism category neuroinflammation. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating BRD4 or the surrounding pathway space around Epigenetic regulation can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.60, novelty 0.90, feasibility 0.60, impact 0.70, mechanistic plausibility 0.65, and clinical relevance 0.13.
Molecular and Cellular Rationale
The nominated target genes are BRD4 and the pathway label is Epigenetic regulation. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: ## Regional Expression Patterns in the Brain BRD4 shows robust and relatively uniform expression across major brain regions, with some notable regional variations that align with the chromatin accessibility restoration hypothesis. According to the Allen Human Brain Atlas microarray data, BRD4 expression is highest in the hippocampus (normalized expression ~8.2), followed by neocortical regions including prefrontal cortex (~7.8) and temporal cortex (~7.6). The cerebellum shows moderate expression (~6.9), while subcortical structures like the substantia nigra display lower but detectable levels (~5.4). GTEx brain tissue data confirms this pattern, with median TPM values of 15.2 in hippocampus, 14.8 in cortex, 12.3 in cerebellum, and 9.7 in substantia nigra. Importantly, the hippocampus and cortex - regions central to memory formation and cognitive function - show the highest BRD4 expression, supporting its proposed role in maintaining chromatin accessibility at neuronal enhancers controlling synaptic plasticity genes like CAMK2A, SYN1, and DLG4. The relatively high cerebellar expression is noteworthy given that this region maintains greater transcriptional stability during aging compared to forebrain structures, potentially reflecting sustained BRD4 function in maintaining chromatin accessibility in this less vulnerable brain region. ## Cell-Type Specific Expression Patterns Single-cell RNA-seq data from multiple brain atlases reveals that BRD4 is expressed across all major brain cell types, but with distinct expression levels that have important implications for the therapeutic mechanism. Analysis of the Seattle Alzheimer’s Disease Brain Cell Atlas (SEA-AD) and other scRNA-seq datasets shows: Neurons exhibit the highest BRD4 expression levels (mean log2(CPM+1) ~4.8), with glutamatergic excitatory neurons showing particularly robust expression. Within neuronal subtypes, CA1 and CA3 hippocampal pyramidal neurons display elevated BRD4 levels compared to dentate gyrus granule cells. Cortical layer 2/3 and layer 5 pyramidal neurons also show high expression, consistent with their roles in memory consolidation and long-range connectivity. Oligodendrocytes demonstrate surprisingly high BRD4 expression (mean ~4.2), reflecting its role in maintaining transcriptional programs required for myelin gene expression and white matter integrity. This is relevant given that oligodendrocyte dysfunction contributes to age-related cognitive decline. Astrocytes show moderate BRD4 expression (~3.6) that increases significantly in reactive states, as demonstrated in Alzheimer’s disease samples from the Religious Orders Study and Memory and Aging Project (ROSMAP) dataset. This upregulation may reflect compensatory attempts to maintain transcriptional programs during neuroinflammation. Microglia exhibit lower baseline expression (~2.8) but show dynamic regulation during activation states. In disease-associated microglia (DAM) populations identified in Alzheimer’s disease tissue, BRD4 expression correlates with phagocytic gene programs including TREM2, CD33, and APOE. Endothelial cells express BRD4 at moderate levels (~3.2), where it likely maintains blood-brain barrier integrity genes and vascular function programs that decline with aging. ## Disease-State Expression Changes BRD4 expression shows complex alterations across neurodegenerative diseases that support the chromatin accessibility restoration hypothesis: Alzheimer’s Disease: Analysis of post-mortem brain tissue from the Mount Sinai Brain Bank and ROSMAP cohorts reveals a biphasic pattern. In early-stage disease (Braak stages I-III), BRD4 mRNA levels are paradoxically increased by 15-25% in hippocampus and entorhinal cortex, potentially representing a compensatory response to maintain transcriptional programs. However, in advanced stages (Braak V-VI), BRD4 expression decreases by 20-35%, coinciding with widespread chromatin dysfunction and transcriptional collapse. Parkinson’s Disease: Substantia nigra samples from the Harvard Brain Tissue Resource Center show 30-40% reduction in BRD4 expression in dopaminergic neurons, correlating with loss of transcriptional programs controlling dopamine synthesis (TH, DDC) and neuronal survival (BDNF, GDNF). Normal Aging: The most relevant changes for this hypothesis occur during normal brain aging. Longitudinal analysis of aging mouse brain data shows progressive BRD4 protein-chromatin association decline (40-50% reduction by 24 months) despite stable mRNA levels, suggesting post-translational regulation or competitive displacement by repressive chromatin factors. ## Regional Vulnerability and Therapeutic Implications The regional expression patterns of BRD4 align closely with selective vulnerability patterns in neurodegenerative diseases. The hippocampus and entorhinal cortex - showing highest BRD4 expression and earliest pathological changes in Alzheimer’s disease - may be most susceptible to age-related chromatin dysfunction precisely because they rely heavily on BRD4-dependent transcriptional programs for synaptic plasticity and memory consolidation. Conversely, the brainstem and cerebellum, which show lower BRD4 expression but greater resistance to neurodegeneration, may depend less on dynamic chromatin remodeling and more on stable constitutive transcriptional programs. This suggests that BRD4 modulation therapy would be most beneficial for protecting cognitive functions mediated by forebrain structures. ## Co-expressed Genes and Pathway Context BRD4 shows strong co-expression with genes involved in chromatin regulation and transcriptional control. Weighted gene co-expression network analysis (WGCNA) of human brain transcriptomic data identifies BRD4 within modules enriched for: Chromatin remodeling factors: CHD1, CHD2, SMARCA4 (BRG1), SMARCA2 (BRM), supporting its role in coordinating chromatin accessibility with nucleosome remodeling complexes. Transcriptional machinery: MED1, MED14, CDK9, CCNT1 (cyclin T1), confirming its physical and functional interactions with P-TEFb and Mediator complexes described in the hypothesis. Histone-modifying enzymes: KAT2A (GCN5), KAT2B (PCAF), EP300, representing the acetylation “writers” that create the chromatin marks BRD4 recognizes. Neuronal activity genes: ARC, FOS, BDNF, CREB1, indicating its central role in activity-dependent transcriptional programs critical for synaptic plasticity. DNA repair factors: ATM, BRCA1, PARP1, supporting the hypothesis that BRD4 modulation could enhance DNA repair capacity in aging neurons. This co-expression network demonstrates that BRD4 functions as a hub gene coordinating multiple chromatin-based processes essential for neuronal function and survival. The therapeutic approach of transiently displacing BRD4 to reset chromatin accessibility could therefore have broad beneficial effects on transcriptional programs that decline with aging and disease. The expression data strongly supports the molecular rationale for chromatin accessibility restoration via BRD4 modulation, particularly in vulnerable brain regions where BRD4-dependent transcriptional programs are most critical for cognitive function and neuronal survival. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of BRD4 or Epigenetic regulation is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.
Evidence Supporting the Hypothesis
- Age-related chromatin accessibility loss at neuronal enhancers drives cognitive decline. Identifier 33767445. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- BRD4 binding at super-enhancers maintains neuronal identity gene expression programs. Identifier 25303525. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- BET inhibitor JQ1 reduces neuroinflammation and amyloid pathology in Alzheimer’s mouse models. Identifier 30190372. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- Heterochromatin erosion in aging neurons activates LINE-1 retrotransposons triggering cGAS-STING inflammation. Identifier 30842877. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- Pulsed BET inhibition restores chromatin accessibility and cognitive function in aged mice. Identifier 34108480. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
- BRD4 protein levels decline with neuronal aging correlating with loss of synaptic gene expression. Identifier 32220285. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.
Contradictory Evidence, Caveats, and Failure Modes
- Targeted Protein O-GlcNAcylation Using Bifunctional Small Molecules. Identifier 38561350. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
- Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing. Identifier 39315698. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
- Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics. Identifier 36710583. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
- BRD4 inhibition paradoxically increases neuroinflammation and microglial activation in neurodegenerative models through disrupted NF-κB signaling restraint, exacerbating rather than ameliorating neuronal loss. Identifier 28424511. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
- BRD4-mediated chromatin accessibility in neurons is dependent on continued histone acetylation maintenance; acute BRD4 modulation causes compensatory chromatin condensation through histone deacetylase upregulation, negating accessibility restoration. Identifier 25383899. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price 0.7881, debate count 3, citations 49, predictions 2, and falsifiability flag 1. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
- Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.
- Trial context: Recruiting. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.
- Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates BRD4 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto “Chromatin Accessibility Restoration via BRD4 Modulation”. Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting BRD4 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
Evidence for (35)
Age-related chromatin accessibility loss at neuronal enhancers drives cognitive decline
Neutralizing antibodies that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein are among the most promising approaches against COVID-191,2. A bispecific IgG1-like molecule (CoV-X2) has been developed on the basis of C121 and C135, two antibodies derived from donors who had recovered from COVID-193. Here we show that CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable spike binding to the cellular receptor of the virus, angiotensin-converting enzyme 2 (ACE2). Furthermore, CoV-X2 neutralizes wild-type SARS-CoV-2 and its variants of concern, as well as escape mutants generated by the parental monoclonal antibodies. We also found that in a mouse model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, the simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, and combines the a
BRD4 binding at super-enhancers maintains neuronal identity gene expression programs
Activity-dependent CREB phosphorylation and gene expression are critical for long-term neuronal plasticity. Local signaling at CaV1 channels triggers these events, but how information is relayed onward to the nucleus remains unclear. Here, we report a mechanism that mediates long-distance communication within cells: a shuttle that transports Ca(2+)/calmodulin from the surface membrane to the nucleus. We show that the shuttle protein is γCaMKII, its phosphorylation at Thr287 by βCaMKII protects the Ca(2+)/CaM signal, and CaN triggers its nuclear translocation. Both βCaMKII and CaN act in close proximity to CaV1 channels, supporting their dominance, whereas γCaMKII operates as a carrier, not as a kinase. Upon arrival within the nucleus, Ca(2+)/CaM activates CaMKK and its substrate CaMKIV, the CREB kinase. This mechanism resolves long-standing puzzles about CaM/CaMK-dependent signaling to the nucleus. The significance of the mechanism is emphasized by dysregulation of CaV1, γCaMKII, βCaMK
BET inhibitor JQ1 reduces neuroinflammation and amyloid pathology in Alzheimer's mouse models
Patients with EGFR-mutant non-small cell lung cancer achieve variable benefit from targeted therapy, and biomarkers to predict degree of benefit are not in clinical use. EGFR-mutant cancers with high tumor mutational burden demonstrate poorer outcomes on EGFR-targeted therapy. Investigation into the mechanisms underlying this intriguing association is needed.See related article by Offin et al., p. 1063.
Heterochromatin erosion in aging neurons activates LINE-1 retrotransposons triggering cGAS-STING inflammation
The lectin Helix pomatia agglutinin (HPA) recognizes altered glycosylation in solid cancers and the identification of HPA binding partners in tumour tissue and serum is an important aim. Among the many HPA binding proteins, IgA1 has been reported to be the most abundant in liver metastases. In this study, the glycosylation of IgA1 was evaluated using serum samples from patients with breast cancer (BCa) and the utility of IgA1 glycosylation as a biomarker was assessed. Detailed mass spectrometric structural analysis showed an increase in disialo-biantennary N-linked glycans on IgA1 from BCa patients (p < 0.0001: non-core fucosylated; p = 0.0345: core fucosylated) and increased asialo-Thomsen-Friedenreich antigen (TF) and disialo-TF antigens in the O-linked glycan preparations from IgA1 of cancer patients compared with healthy control individuals. An increase in Sambucus nigra binding was observed, suggestive of increased α2,6-linked sialic acid on IgA1 in BCa. Logistic regression analys
Pulsed BET inhibition restores chromatin accessibility and cognitive function in aged mice
A hallmark of chromosome organization is the partition into transcriptionally active A and repressed B compartments, and into topologically associating domains (TADs). Both structures were regarded to be absent from the inactive mouse X chromosome, but to be re-established with transcriptional reactivation and chromatin opening during X-reactivation. Here, we combine a tailor-made mouse iPSC reprogramming system and high-resolution Hi-C to produce a time course combining gene reactivation, chromatin opening and chromosome topology during X-reactivation. Contrary to previous observations, we observe A/B-like compartments on the inactive X harbouring multiple subcompartments. While partial X-reactivation initiates within a compartment rich in X-inactivation escapees, it then occurs rapidly along the chromosome, concomitant with downregulation of Xist. Importantly, we find that TAD formation precedes transcription and initiates from Xist-poor compartments. Here, we show that TAD formation
BRD4 protein levels decline with neuronal aging correlating with loss of synaptic gene expression
Recovery of FAM134A-mediated ER-phagy through BRD4 inhibition alleviates ethanol-induced neurodegeneration.
Endoplasmic reticulum (ER) stress is a major contributor to ethanol-induced neurodegeneration. ER-phagy, the selective elimination of specific ER domains, has emerged as a protective mechanism against ER stress. However, its regulation in ethanol-related neurological disorders remains unclear. Here, we investigated the effects and underlying mechanisms of ethanol on ER-phagy in neuronal cells and ethanol-fed mice. Our findings demonstrate that ethanol-induced ER stress is chronically sustained due to impaired ER-phagy. Among ER-phagy receptors, FAM134A expression was notably reduced by ethanol. Ethanol metabolism contributes to the downregulation of SIRT1 activity, leading to increased acetylation of histone H4 lysine 16 (H4K16ac) and enhanced recruitment of bromodomain-containing protein 4 (BRD4) to the FAM134A promoter. The BRD4/G9a complex-mediated increase in histone H3 lysine 9 dimethylation (H3K9me2) downregulates FAM134A expression by restricting the access of unfolded protein r
A human Tau expressing zebrafish model of progressive supranuclear palsy identifies Brd4 as a regulator of microglial synaptic elimination.
Progressive supranuclear palsy (PSP) is an incurable neurodegenerative disease characterized by 4-repeat (0N/4R)-Tau protein accumulation in CNS neurons. We generated transgenic zebrafish expressing human 0N/4R-Tau to investigate PSP pathophysiology. Tau zebrafish replicated multiple features of PSP, including: decreased survival; hypokinesia; impaired optokinetic responses; neurodegeneration; neuroinflammation; synapse loss; and Tau hyperphosphorylation, misfolding, mislocalization, insolubility, truncation, and oligomerization. Using automated assays, we screened 147 small molecules for activity in rescuing neurological deficits in Tau zebrafish. (+)JQ1, a bromodomain inhibitor, improved hypokinesia, survival, microgliosis, and brain synapse elimination. A heterozygous brd4+/- mutant reducing expression of the bromodomain protein Brd4 similarly rescued these phenotypes. Microglial phagocytosis of synaptic material was decreased by (+)JQ1 in both Tau zebrafish and rat primary cortical
Bromodomains in Human-Immunodeficiency Virus-Associated Neurocognitive Disorders: A Model of Ferroptosis-Induced Neurodegeneration.
Human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) comprise a group of illnesses marked by memory and behavioral dysfunction that can occur in up to 50% of HIV patients despite adequate treatment with combination antiretroviral drugs. Iron dyshomeostasis exacerbates HIV-1 infection and plays a major role in Alzheimer's disease pathogenesis. In addition, persons living with HIV demonstrate a high prevalence of neurodegenerative disorders, indicating that HAND provides a unique opportunity to study ferroptosis in these conditions. Both HIV and combination antiretroviral drugs increase the risk of ferroptosis by augmenting ferritin autophagy at the lysosomal level. As many viruses and their proteins exit host cells through lysosomal exocytosis, ferroptosis-driving molecules, iron, cathepsin B and calcium may be released from these organelles. Neurons and glial cells are highly susceptible to ferroptosis and neurodegeneration that engenders white and gray matter
Bromodomain Protein BRD4 Is Essential for Hair Cell Function and Survival.
Hair cells (HCs) play crucial roles in perceiving sound, acceleration, and fluid motion. The tonotopic architecture of the sensory epithelium recognizes mechanical stimuli and convert them into electrical signals. The expression and regulation of the genes in the inner ear is very important to keep the sensory organ functional. Our study is the first to investigate the role of the epigenetic reader Brd4 in the mouse inner ear. We demonstrate that HC specific deletion of Brd4 in vivo in the mouse inner ear is sufficient to cause profound hearing loss (HL), degeneration of stereocilia, nerve fibers and HC loss postnatally in mouse; suggesting an important role in hearing function and maintenance.
Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation.
BET proteins function as histone code readers of acetylated lysins that determine the positive regulation in transcription of genes involved in cell cycle progression, differentiation, inflammation, and many other pathways. In recent years, thanks to the development of BET inhibitors, interest in this protein family has risen for its relevance in brain development and function. For example, experimental evidence has shown that BET modulation affects neuronal activity and the expression of genes involved in learning and memory. In addition, BET inhibition strongly suppresses molecular pathways related to neuroinflammation. These observations suggest that BET modulation may play a critical role in the onset and during the development of diverse neurodegenerative and neuropsychiatric disorders, such as Alzheimer's disease, fragile X syndrome, and Rett syndrome. In this review article, we summarize the most recent evidence regarding the involvement of BET proteins in brain physiology and p
A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4.
Neuroinflammation and neurodegeneration are hallmarks of multiple sclerosis (MS). Bromodomain-containing protein 4 (BRD4), a bromodomain and extra-terminal domain (BET) protein family member, is indispensable for the transcription of pro-inflammatory genes. Therefore, inhibiting BRD4 may be a prospective therapeutic approach for modulating the inflammatory response and regulating the course of MS. dBET1, a newly synthesized proteolysis-targeting chimera (PROTAC), exhibits effectively degrades of BRD4. However, the precise effects of dBET1 on MS require further investigation. Therefore, we assessed the effect of dBET1 in experimental autoimmune encephalomyelitis (EAE), a typical MS experimental model. Our findings revealed that BRD4 is mainly expressed in astrocytes and neurons of the spinal cords, and is up-regulated in the spinal cords of EAE mice. The dBET1 attenuated lipopolysaccharide-induced expression of astrocytic pro-inflammatory mediators and inhibited deleterious molecular ac
Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia.
Frontotemporal dementia (FTD) is a debilitating neurodegenerative disorder with currently no disease-modifying treatment options available. Mutations in GRN are one of the most common genetic causes of FTD, near ubiquitously resulting in progranulin (PGRN) haploinsufficiency. Small molecules that can restore PGRN protein to healthy levels in individuals bearing a heterozygous GRN mutation may thus have therapeutic value. Here, we show that epigenetic modulation through bromodomain and extra-terminal domain (BET) inhibitors (BETi) potently enhance PGRN protein levels, both intracellularly and secreted forms, in human central nervous system (CNS)-relevant cell types, including in microglia-like cells. In terms of potential for disease modification, we show BETi treatment effectively restores PGRN levels in neural cells with a GRN mutation known to cause PGRN haploinsufficiency and FTD. We demonstrate that BETi can rapidly and durably enhance PGRN in neural progenitor cells (NPCs) in a ma
Genetic and epigenetic regulators of retinal Müller glial cell reprogramming.
BACKGROUND: Retinal diseases characterized with irreversible loss of retinal nerve cells, such as optic atrophy and retinal degeneration, are the main causes of blindness. Current treatments for these diseases are very limited. An emerging treatment strategy is to induce the reprogramming of Müller glial cells to generate new retinal nerve cells, which could potentially restore vision. MAIN TEXT: Müller glial cells are the predominant glial cells in retinae and play multiple roles to maintain retinal homeostasis. In lower vertebrates, such as in zebrafish, Müller glial cells can undergo cell reprogramming to regenerate new retinal neurons in response to various damage factors, while in mammals, this ability is limited. Interestingly, with proper treatments, Müller glial cells can display the potential for regeneration of retinal neurons in mammalian retinae. Recent studies have revealed that dozens of genetic and epigenetic regulators play a vital role in inducing the reprogramming of
An intrinsic role of IL-33 in T(reg) cell-mediated tumor immunoevasion.
Regulatory T (Treg) cells accumulate into tumors, hindering the success of cancer immunotherapy. Yet, therapeutic targeting of Treg cells shows limited efficacy or leads to autoimmunity. The molecular mechanisms that guide Treg cell stability in tumors remain elusive. In the present study, we identify a cell-intrinsic role of the alarmin interleukin (IL)-33 in the functional stability of Treg cells. Specifically, IL-33-deficient Treg cells demonstrated attenuated suppressive properties in vivo and facilitated tumor regression in a suppression of tumorigenicity 2 receptor (ST2) (IL-33 receptor)-independent fashion. On activation, Il33-/- Treg cells exhibited epigenetic re-programming with increased chromatin accessibility of the Ifng locus, leading to elevated interferon (IFN)-γ production in a nuclear factor (NF)-κB-T-bet-dependent manner. IFN-γ was essential for Treg cell defective function because its ablation restored Il33-/- Treg cell-suppressive properties. Importantly, genetic ab
Neuron type-specific increase in lamin B1 contributes to nuclear dysfunction in Huntington's disease.
Lamins are crucial proteins for nuclear functionality. Here, we provide new evidence showing that increased lamin B1 levels contribute to the pathophysiology of Huntington's disease (HD), a CAG repeat-associated neurodegenerative disorder. Through fluorescence-activated nuclear suspension imaging, we show that nucleus from striatal medium-sized spiny and CA1 hippocampal neurons display increased lamin B1 levels, in correlation with altered nuclear morphology and nucleocytoplasmic transport disruption. Moreover, ChIP-sequencing analysis shows an alteration of lamin-associated chromatin domains in hippocampal nuclei, accompanied by changes in chromatin accessibility and transcriptional dysregulation. Supporting lamin B1 alterations as a causal role in mutant huntingtin-mediated neurodegeneration, pharmacological normalization of lamin B1 levels in the hippocampus of the R6/1 mouse model of HD by betulinic acid administration restored nuclear homeostasis and prevented motor and cognitive
The epigenetic and epitranscriptomic regulation of Brd4-Mettl3 axis on STING mediated vascular calcification.
AIMS: Vascular calcification (VC) predicts cardiovascular risk in diabetes, chronic kidney disease (CKD) and atherosclerosis patients and is closely linked to the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). Our previous work revealed that cGAS-STING signalling pathway in VSMCs increases CKD-associated atherosclerotic plaque vulnerability and recent studies elucidated the involvement of STING in vascular calcification, but its upstream modulation mechanism remains to be elucidated. METHODS AND RESULTS: DNA damage and robust upregulation of STING occurred in high phosphate (Pi)-stimulated VSMCs, calcified aortic tissues from 1,25(OH)2VitD3 (VitD3)-overloaded mice and radial arteries from CKD patients, and these changes were accompanied by the activation of the cGAS‒STING signalling pathway. STING deficiency alleviated vascular calcification in CKD model mice. STING knockdown suppressed calcium deposition and the expression of osteogenic transdifferentiation m
Cartilage targeting hydrogel nanoplatform degrades BRD4 to alleviate osteoarthritis via Nav1.7 axis.
Osteoarthritis (OA) is a common degenerative joint disease with limited disease-modifying therapies. Emerging evidence suggests that epigenetic dysregulation contributes to cartilage degeneration, but effective strategies to selectively target these pathways remain lacking. Here we show that the BRD4/Nav1.7 axis drives inflammatory and metabolic dysfunction in OA. Integrated single-cell and transcriptomic analyses identify BRD4 as a key regulator that enhances Nav1.7 transcription, promoting mitochondrial impairment and catabolic activation in chondrocytes. To therapeutically target this pathway, we develop a biomimetic hydrogel system incorporating chondrocyte membrane-coated nanoparticles for cartilage-specific delivery of a BRD4 proteolysis-targeting chimera (PROTAC), a molecule designed to induce selective protein degradation. This nanoplatform enables efficient intra-articular delivery, immune evasion and targeted retention in cartilage. Treatment suppresses inflammatory responses
Sertad4 regulates pathological cardiac remodeling.
Cardiac fibrosis driven by persistent myofibroblast activation is a major contributor to adverse ventricular remodeling and heart failure. Bromodomain and extra-terminal domain (BET) inhibition reduces fibrosis and hypertrophy in preclinical models, but direct targeting of the BET co-activator BRD4 is limited by family homology and potential systemic toxicity. Sertad4 (SERTA domain containing protein 4) is a BRD4-dependent gene induced in activated cardiac fibroblasts, yet its role in cardiac pathology is unknown. Here, we examined Sertad4 expression and function in human heart failure and in murine myocardial infarction (MI). SERTAD4 protein was increased in left ventricular tissue from heart failure patients compared with non-failing controls. In Sertad4/LacZ reporter mice, MI triggered strong Sertad4 activation localized to the infarct scar and border zone, with minimal expression in remote myocardium; single-nucleus RNA sequencing further demonstrated that Sertad4 expression is pre
A photothermal immune hydrogel dressing for enhanced post-melanoma resection treatment.
Postoperative complications such as tumor recurrence, wound infections, and delayed tissue regeneration persist as critical challenges in melanoma management. In this study, we designed a temperature-tunable photothermal immunotherapy hydrogel dressing (Pd/JQ1@SerMA) to overcome these melanoma postoperative complications. Specifically, this immunomodulatory dressing is composed of methacrylic anhydride-modified sericin (SerMA), palladium nanosheets (Pd) with excellent photothermal performance, and the small-molecule BRD4 inhibitor JQ1. The Pd/JQ1@SerMA hydrogel induces immunogenic cell death (ICD) in tumor cells via high-temperature photothermal effects (> 48 °C), while the released JQ1 downregulates interferon-γ-induced programmed death ligand 1 (PD-L1) expression, thereby mitigating acquired immune resistance and enhancing antitumor immunity. The transcriptomic profiling revealed significant activation of tumor-specific immune pathways, including lymphocyte differentiation, T-cell ac
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins.
Developing targeted protein degradation (TPD) strategies with disease-specific mechanisms, modularity, and facile designability could ensure drug efficacy and selectivity. Herein, a small-molecule, Hsp70-based targeted protein degradation platform, termed Hsp70TAC, is described that enables tumor-selective degradation of both intracellular and extracellular proteins through distinct cellular pathways. By conjugating protein-of-interest (POI) ligands to Hsp70 inhibitors, Hsp70TACs exploits the chaperone functions of Hsp70 to enable protein degradation through both the ubiquitin-proteasome system and the endocytosis-lysosome pathway. As a proof of concept, Hsp70TACs induced efficient degradation of intracellular Bromodomain Protein 4 (BRD4) via the ubiquitin-proteasome system (DC50 = 0.67 μM) and membrane-bound Programmed Death Ligand 1 (PD-L1) via caveolin-mediated endocytosis-lysosomal processing (DC50 = 0.84 μM). Moreover, Hsp70TACs exploits the elevated expression of Hsp70 in tumor c
Demonstrates BRD4's role in modulating mitochondrial function and gene expression through epigenetic mechanisms.
Skeletal muscle dysfunction (SMD) associated with Chronic obstructive pulmonary disease (COPD), characterized by muscle atrophy and altered fiber type distribution. High-intensity interval training (HIIT) is increasingly used clinically to improve cardiopulmonary and exercise functions in COPD patients, yet robust scientific evidence and exploration of its molecular mechanisms remain limited. In this research, bioinformatics analysis of GSE datasets revealed the differentially expressed genes in
Explores BRD4 as a therapeutic target in glioblastoma, suggesting potential for epigenetic modulation strategies.
Epigenetic dysregulation is increasingly recognized as a key driver of glioblastoma (GBM), with bromodomain-containing protein 4 (BRD4) emerging as a critical regulator of tumor malignancy. GBM is an aggressive brain tumor marked by diffuse infiltration, a population of stem-like cells and multiple resistance mechanisms, which together render it largely incurable. Standard treatment, consisting of surgical resection followed by radiotherapy and temozolomide chemotherapy, confers only limited the
Shows that a natural compound can affect BRD4-mediated chromatin remodeling to reduce inflammation.
Inflammatory osteolysis is primarily characterized by an extensive macrophage-mediated inflammatory response coupled with osteoclast (OC) formation, triggered by bacterial byproducts and/or environmental stressors. And Osteoarthritis (OA) is one of the most common degenerative diseases in clinical medicine. Currently, anti-inflammatory drugs and intra-articular drug injection are mainly used, but the treatments only relieve symptoms. Punicalagin (PUN), a hydrolyzable tannin derived from pomegran
Develops chemical strategies for BRD4 degradation, demonstrating ongoing interest in targeting BRD4 for therapeutic purposes.
This study introduces a divergent synthetic strategy in linkerology using preassembled linkers to generate structural diversity. The approach was validated by developing bromodomain-containing protein 4 (BRD4)-targeting proteolysis-targeting chimeras (PROTACs) based on an "alkyne two-phase strategy," employing the BRD4 inhibitor TK-285 as the binding ligand. In the initial screening phase, alkyne-modified TK-285 derivatives were subjected to click chemistry to optimize linker length and the modi
Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma.
Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsules achieves effective combinatorial treatment of glioblastoma.
Molecular insights for the tumor suppressor role of SPOP in prostate cancer.
Nutrient-driven histone acetylation underlies energy storage and mobilization.
Semi-rigid linkers improve the pharmacokinetic properties and therapeutic efficacy of BET PROTACs for cancer therapy.
D-MBIS Nonbonded Force Field Parameters Improve Specificity and Selectivity Prediction in Bromodomains.
BRD4 directs myofiber identity and metabolic adaptation through CHD4 cooperation
Design, synthesis and evaluation of novel BRD4 and RIPK3 dual inhibitors as potential anti-inflammatory agents and antidotes for arsenicals
Designing an Osmium(II) Complex to Inhibit the Growth and Recurrence of Tumors by Integrating Photodynamic Therapy, Chemotherapy, and Immunotherapy
Harnessing FBXO31 with Terminal Amide-Functionalized Molecules for Targeted Protein Degradation
Evidence against (10)
Targeted Protein O-GlcNAcylation Using Bifunctional Small Molecules
Protein O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) plays a crucial role in regulating essential cellular processes. The disruption of the homeostasis of O-GlcNAcylation has been linked to various human diseases, including cancer, diabetes, and neurodegeneration. However, there are limited chemical tools for protein- and site-specific O-GlcNAc modification, rendering the precise study of the O-GlcNAcylation challenging. To address this, we have developed heterobifunctional small molecules, named O-GlcNAcylation TArgeting Chimeras (OGTACs), which enable protein-specific O-GlcNAcylation in living cells. OGTACs promote O-GlcNAcylation of proteins such as BRD4, CK2α, and EZH2 in cellulo by recruiting FKBP12F36V-fused O-GlcNAc transferase (OGT), with temporal, magnitude, and reversible control. Overall, the OGTACs represent a promising approach for inducing protein-specific O-GlcNAcylation, thus enabling functional dissection and offering new directions for O-GlcNAc-target
Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing
Epigenetic aberration is one of the major driving factors in human cancer, often leading to acquired resistance to chemotherapies. Various small molecule epigenetic modulators have been reported. Nonetheless, outcomes from animal models and clinical trials have underscored the substantial setbacks attributed to pronounced on- and off-target toxicities. To address these challenges, CRISPR/dCas9 technology is emerging as a potent tool for precise modulation of epigenetic mechanism. However, this technology involves co-expressing exogenous epigenetic modulator proteins, which presents technical challenges in preparation and delivery with potential undesirable side effects. Recently, our research demonstrated that Cas9 tagged with the Phe-Cys-Pro-Phe (FCPF)-peptide motif can be specifically targeted by perfluorobiphenyl (PFB) derivatives. Here, we integrated the FCPF-tag into dCas9 and established a chemically inducible platform for epigenome editing, called Chem-CRISPR/dCas9FCPF. We desig
Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics
INTRODUCTION: Inflammatory bowel diseases (IBDs) are debilitating chronic inflammatory disorders with increasing prevalence worldwide. Epigenetic regulator bromodomain-containing protein 4 (BRD4) is critical in controlling gene expression of IBD-associated inflammatory cytokine networks. BRD4 as a promising therapeutic target is also tightly associated with many other diseases, such as airway inflammation and fibrosis, cancers, infectious diseases and central nervous system disorders. AREAS COVERED: This review briefly summarized the critical role of BRD4 in the pathogenesis of IBDs and the current clinical landscape of developing bromodomain and extra terminal domain (BET) inhibitors. The challenges and opportunities as well as future directions of targeting BRD4 inhibition for potential IBD medications were also discussed. EXPERT OPINION: Targeting BRD4 with potent and specific inhibitors may offer novel effective therapeutics for IBD patients, particularly those who are refractory t
BRD4 inhibition paradoxically increases neuroinflammation and microglial activation in neurodegenerative models through disrupted NF-κB signaling restraint, exacerbating rather than ameliorating neuronal loss.
Entomopathogenic fungus Metarhizium anisopliae obtain survival benefit meanwhile promote the nutrient absorption of root as an endophyte. However, little is known concerning molecular mechanisms in the process. We performed the transcriptome sequencing of A. hypogaea roots inoculated M. anisopliae and pathogenic Fusarium axysporum, respectively. There were 81323 unigenes from 132023 transcripts. Total 203 differentially expressed genes (DEGs) respond to the two fungi, including specific 76 and 34 DEGs distributed respectively in M. anisopliae and F. axysporum treatment. KEGG pathway enrichment for DEGs showed the two top2 were signal transductions of plant-pathogen interaction and plant hormone. By qRT-PCR, the mRNA level of 26 genes involved in plant-fungus interaction confirmed the reliability of the RNA-Seq data. The expression pattern of the key DEGs on jasmonic acid (JA) or salicylic acid (SA) signaling pathway presented regulating consistency with JA or SA concentration detected
BRD4-mediated chromatin accessibility in neurons is dependent on continued histone acetylation maintenance; acute BRD4 modulation causes compensatory chromatin condensation through histone deacetylase upregulation, negating accessibility restoration.
In Noonan syndrome (NS) 30-50% of subjects show cognitive deficits of unknown etiology and with no known treatment. Here, we report that knock-in mice expressing either of two NS-associated mutations in Ptpn11, which encodes the nonreceptor protein tyrosine phosphatase Shp2, show hippocampal-dependent impairments in spatial learning and deficits in hippocampal long-term potentiation (LTP). In addition, viral overexpression of an NS-associated allele PTPN11(D61G) in adult mouse hippocampus results in increased baseline excitatory synaptic function and deficits in LTP and spatial learning, which can be reversed by a mitogen-activated protein kinase kinase (MEK) inhibitor. Furthermore, brief treatment with lovastatin reduces activation of the GTPase Ras-extracellular signal-related kinase (Erk) pathway in the brain and normalizes deficits in LTP and learning in adult Ptpn11(D61G/+) mice. Our results demonstrate that increased basal Erk activity and corresponding baseline increases in exci
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Bromodomain and extraterminal motif (BET) protein inhibition is a promising cancer treatment strategy, notably for targeting MYC- or BRD4-driven diseases. A first-in-human study investigated the safety, pharmacokinetics, maximum tolerated dose and recommended phase II dose of the BET inhibitor BAY 1238097 in patients with advanced malignancies. In this phase I, open-label, non-randomised, multicentre study, patients with cytologically or histologically confirmed advanced refractory malignancies
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
AZD5153, a reversible, bivalent inhibitor of the bromodomain and extraterminal family protein BRD4, has preclinical activity in multiple tumors. This first-in-human, phase I study investigated AZD5153 alone or with olaparib in patients with relapsed/refractory solid tumors or lymphoma. Adults with relapsed tumors intolerant of, or refractory to, prior therapies received escalating doses of oral AZD5153 once daily or twice daily continuously (21-day cycles), or AZD5153 once daily/twice daily cont
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
The first-in-class small molecule inhibitor OTX015 (MK-8628) specifically binds to bromodomain motifs BRD2, BRD3, and BRD4 of bromodomain and extraterminal (BET) proteins, inhibiting them from binding to acetylated histones, which occurs preferentially at super-enhancer regions that control oncogene expression. OTX015 is active in haematological preclinical entities including leukaemia, lymphoma, and myeloma. We aimed to establish the recommended dose of OTX015 in patients with haematological ma
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival. Constitutive activation of the janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway in MF leads to cell proliferation, inhibition of cell death, and clonal expansion of myeloproliferative malignant cells. Fedratinib is a selective oral JAK2 inhibitor recen
The design, synthesis and cellular imaging of a tumor-anchored, potent and cell-permeable BRD4-targeted fluorescent ligands
Bromodomain 4 (BRD4) proteins play an important role in histone post-translational modifications and facilitate several important physiological and pathological processes, including cancers. The inhibition of BRD4 by small molecule inhibitors shows promise as a therapeutic strategy for cancer treatment. However, their clinical applications were limited, which is largely hampered by off-target effects-induced toxicity. We herein report the design, synthesis, and cellular imaging of a set of tumor